Evidence map›Paper›PMID 24918772›Full record

ArticlePloS one2014

Differential neutralizing activities of a single domain camelid antibody (VHH) specific for ricin toxin's binding subunit (RTB).

Cristina Herrera, David J Vance, Leslie E Eisele, Charles B Shoemaker, Nicholas J Mantis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Cristina HerreraDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America; Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York, United States of America.
David J VanceDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Leslie E EiseleScientific Cores, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Charles B ShoemakerDepartment of Infectious Disease and Global Health, Tufts Cummings School of Veterinary Medicine, North Grafton, Massachusetts, United States of America.
Nicholas J MantisDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America; Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York, United States of America.
Wadsworth Center · USNew England Disabled Sports · USNew York State Department of Health · USUniversity at Albany, State University of New York · US

Funding

Ricin toxin: Neutralizing antibodies and vaccine designR03AI097688 · NIAID · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2012 to 2013
$136k
NIAID NIH HHS AI097688NIAID NIH HHS R03 AI097688
6 · The paper itself

Abstract

Ricin, a member of the A-B family of ribosome-inactivating proteins, is classified as a Select Toxin by the Centers for Disease Control and Prevention because of its potential use as a biothreat agent. In an effort to engineer therapeutics for ricin, we recently produced a collection of alpaca-derived, heavy-chain only antibody VH domains (VHH or "nanobody") specific for ricin's enzymatic (RTA) and binding (RTB) subunits. We reported that one particular RTB-specific VHH, RTB-B7, when covalently linked via a peptide spacer to different RTA-specific VHHs, resulted in heterodimers like VHH D10/B7 that were capable of passively protecting mice against a lethal dose challenge with ricin. However, RTB-B7 itself, when mixed with ricin at a 1 ∶ 10 toxin:antibody ratio did not afford any protection in vivo, even though it had demonstrable toxin-neutralizing activity in vitro. To better define the specific attributes of antibodies associated with ricin neutralization in vitro and in vivo, we undertook a more thorough characterization of RTB-B7. We report that RTB-B7, even at 100-fold molar excess (toxin:antibody) was unable to alter the toxicity of ricin in a mouse model. On the other hand, in two well-established cytotoxicity assays, RTB-B7 neutralized ricin with a 50% inhibitory concentration (IC50) that was equivalent to that of 24B11, a well-characterized and potent RTB-specific murine monoclonal antibody. In fact, RTB-B7 and 24B11 were virtually identical when compared across a series of in vitro assays, including adherence to and neutralization of ricin after the toxin was pre-bound to cell surface receptors. RTB-B7 differed from both 24B11 and VHH D10/B7 in that it was relatively less effective at blocking ricin attachment to receptors on host cells and was not able to form high molecular weight toxin:antibody complexes in solution. Whether either of these activities is important in ricin toxin neutralizing activity in vivo remains to be determined.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBinding Sites, AntibodyCell LineCell Line, TumorChlorocebus aethiopsFemaleHumansImmunoglobulin Heavy ChainsMiceMice, Inbred BALB CRibosome Inactivating ProteinsRicinVero CellsAntibodies, MonoclonalAntibodies, NeutralizingImmunoglobulin Heavy ChainsRibosome Inactivating ProteinsRicin

Identifiers

PMID24918772
PMCPMC4053406
OpenAlexW2011027034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.